Drug Trial Radar · NCT04937153
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jun 15, 2021
Primary completion
Oct 1, 2024
Study completion Oct 1, 2024
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Jun 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with pembrolizumab in Japanese study participants with malignant solid tumors.
Conditions
- Solid Tumor
Interventions
AcasunlimabBiological
Acasunlimab will be administered intravenously (IV) once every 21 days.
PembrolizumabBiological
Pembrolizumab will be administered IV once every 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose limiting Toxicities (DLTs)Time frame: During first cycle (Cycle length=21 days) in each cohort
- Number of Participants with Adverse Events (AEs)Time frame: From first dose date up to end of the safety follow up period, 90 days after last dose
- Area under the concentration time curve (AUC) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
- Maximum (Peak) Plasma Concentration (Cmax) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
- Time to Reach Cmax (Tmax) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
- Plasma Trough (Pre-dose) Concentrations (Cthrough) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
- Elimination half-life (t 1/2) of AcasunlimabTime frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center East
Chiba, Japan
National Cancer Center Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.